Genetic studies identify a causative mutation in 30-40% of familial dilated cardiomyopathy cases, highlighting the importance of genetic screening and family history evaluation.
Genetic testing is a crucial tool in familial dilated cardiomyopathy, identifying causative mutations in 30-40% of cases and guiding family screening.
INTRODUCTION: Dilated cardiomyopathy (DCM) is the most common cardiomyopathy and occurs often in families. As an inherited disease, understanding the significance of diagnostic procedures and genetic screening within families is of utmost importance. AREAS COVERED: Genetic studies have shown that in 30-40% of familial DCM (FDC) cases a causative genetic mutation can be identified. Successful genetic analysis is highly dependent on close examination of patient and family history, and clinical guidelines exist recommending genetic testing to aid in the evaluation of family members at risk of developing FDC. Clinical genetic testing offers a resource for families to identify the etiology of their disease, and in some cases may provide clinical prognostic insight. EXPERT OPINION: As an inherited disease, future FCD studies will focus on elucidating the remaining 60-70% of genetic causes in inherited cases and the pathogenic mechanisms leading to the phenotype. Specifically, a focus on regulatory regions, copy number variation, genetic and environmental modifiers and functional confirmatory investigations will be essential.
Sweet et al. (Mon,) conducted a review in Familial dilated cardiomyopathy. Genetic screening was evaluated. Genetic studies identify a causative mutation in 30-40% of familial dilated cardiomyopathy cases, highlighting the importance of genetic screening and family history evaluation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: